Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer

European Journal of Cancer Prevention

Volumn 22, Issue 6, 2013, Pages 540-548

  Tang, Dongfang ^a   Shen, Yi ^a   Wang, Mingzhao ^a   Yang, Ronghua ^a   Wang, Zizong ^a   Sui, Aihua ^a   Jiao, Wenjie ^a   Wang, Yongjie ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

biomarker; early detection; lung cancer; microRNA

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 155; MICRORNA 21; RNA DIRECTED DNA POLYMERASE;

AGED; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; EARLY DIAGNOSIS; FEMALE; HUMAN; LUNG CANCER; LUNG NODULE; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; PLASMA; PRIORITY JOURNAL; PRODUCTIVITY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SMOKING; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84885175452     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32835f3be9     Document Type: Article

References (28)

1. Banerjee N, Talcott S, Safe S, Mertens-Talcott SU (2012). Cytotoxicity of pomegranate polyphenolics in breast cancer cells in vitro and vivo: Potential role of miRNA-27a and miRNA-155 in cell survival and inflammation. Breast Cancer Res Treat 136:21-34.
2. Barbareschi M, Cantaloni C, Del Vescovo V, Cavazza A, Monica V, Carella R, et al. (2011). Heterogeneity of large cell carcinoma of the lung: An immunophenotypic and miRNA-based analysis. Am J Clin Pathol 136:773-782.
3. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, et al. (2011). MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA. 108:3713-3718.
4. Boeri M, Pastorino U, Sozzi G (2012). Role of microRNAs in lung cancer: MicroRNA signatures in cancer prognosis. Cancer J 18:268-274.
5. Chen Z, Zeng H, Guo Y, Liu P, Pan H, Deng A, Hu J (2010). miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-myc. J Exp Clin Cancer Res 29:151.
6. Cho WC (2011). Promises and challenges in developing miRNA as a molecular diagnostic tool for lung cancer. Expert Rev Mol Diagn 11:763-766.
7. Cho WC, Chow AS, Au JS (2011). MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol 8:125-131.
8. Dahlgaard J, Mazin W, Jensen T, Pohl M, Bshara W, Hansen A, et al. (2011). Analytical variables influencing the performance of a miRNA based laboratory assay for prediction of relapse in stage I non-small cell lung cancer (NSCLC). BMC Res Notes 4:424-435.
9. Donnem T, Fenton CG, Lonvik K, Berg T, Eklo K, Andersen S, et al. (2012). MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. PLoS ONE 7:e29671.
10. Du L, Schageman JJ, Irnov I, Girard L, Hammond SM, Minna JD, et al. (2010). MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs. J Exp Clin Cancer Res 29:75.
11. Frezzetti D, De Menna M, Zoppoli P, Guerra C, Ferraro A, Bello AM, et al. (2011). Upregulation of miR-21 by Ras in vivo and its role in tumor growth. Oncogene 30:275-286.
12. Gao W, Xu J, Shu YQ (2011). miRNA expression and its clinical implications for the prevention and diagnosis of non-small-cell lung cancer. Expert Rev Respir Med 5:699-709.
13. Hata A, Davis BN (2010). Regulation of pri-miRNA processing through Smads. Adv Exp Med Biol 700:15-27.
14. Heneghan HM, Miller N, Kerin MJ (2010). Circulating miRNA signatures: Promising prognostic tools for cancer. J ClinOncol 28:e573-e574, [author reply e5-e6].
15. Hsu CM, Lin PM, Wang YM, Chen ZJ, Lin SF, Yang MY (2012). Circulating miRNA is a novel marker for head and neck squamous cell carcinoma. Tumour Biol 33:1933-1942.
16. Hubbard MO, Fu P, Margevicius S, Dowlati A, Linden PA (2012). Five-year survival does not equal cure in non-small cell lung cancer: A surveillance, epidemiology, and end results-based analysis of variables affecting 10- to 18-year survival. J Thorac Cardiovasc Surg 143:1307-1313.
17. Iorio MV, Croce CM (2012). MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4:143-159.
18. Li M, Xiao T, Zhang Y, Feng L, Lin D, Liu Y, et al. (2010). Prognostic significance of matrix metalloproteinase-1 levels in peripheral plasma and tumour tissues of lung cancer patients. Lung Cancer 69:341-347.
19. Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A, et al. (2011). Targeting tumor hypoxia: Suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 71: 3364-3376.
20. Tan LP,Wang M, Robertus JL, Schakel RN, Gibcus JH, Diepstra A, et al. (2009). miRNA profiling of B-cell subsets: Specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes. Lab Invest 89:708-716.
21. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, et al. (2010). Reprogramming of miRNA networks in cancer and leukemia. Genome Res 20:589-599.
22. Wang XC, Tian LL,Wu HL, Jiang XY, Du LQ, Zhang H, et al. (2010). Expression of miRNA-130a in nonsmall cell lung cancer. Am J Med Sci 340:385-388.
23. Wei J, Gao W, Zhu CJ, Liu YQ, Mei Z, Cheng T, Shu YQ (2011). Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer 30:407-414.
24. Wu Y, Crawford M, Yu B, Mao Y, Nana-Sinkam SP, Lee LJ (2011). MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol Pharm 8:1381-1389.
25. Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, et al. (2010). Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 67:170-176.
26. Xue C, Hu Z, Jiang W, Zhao Y, Xu F, Huang Y, et al. (2012). National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer 77:371-375.
27. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer cell 9:189-198.
28. Yang ZY, Hu SL, Shi W, Zhu BL, Xu JY, Zhang YJ (2011). The clinical value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in postoperative patients with gastrointestinal mucinous adenocarcinoma. Nucl Med Commun 32:1018-1025.